ArticleMemorias do Instituto Oswaldo Cruz2017
Minimal inhibitory concentration distributions and epidemiological cutoff values of five antifungal agents against Sporothrix brasiliensis.
Article in Memorias do Instituto Oswaldo Cruz, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Emergence of difficult-to-treat lymphocutaneous sporotrichosis? Analysis based on three cases with high and low MIC Sporothrix brasiliensis isolates.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Article
- Adjuvant hyperbaric oxygen therapy reduces the duration of sporotrichosis treatment.PLoS neglected tropical diseases · 2025Article
- In vitro effects of the new antifungal compound manogepix (APX001) against the three most clinically relevant species of Sporothrix.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- In Vitro Evidence for the Efficacy of Manuka Honey and Its Components Against the Major Human PathogenicPharmaceuticals (Basel, Switzerland) · 2025Article
- Evidence of Clinical and Laboratory Correlation of Itraconazole Resistance inMicroorganisms · 2024Article
- Bimodal distribution of azole susceptibility inAntimicrobial agents and chemotherapy · 2024Article
- Whole transcriptome sequencing for revealing the pathogenesis of sporotrichosis caused by Sporothrix globosa.Scientific reports · 2024Article
- Article
- Sporotrichosis in the nasal mucosa: A single-center retrospective study of 37 cases from 1998 to 2020.PLoS neglected tropical diseases · 2023Article
- Sporotrichosis Outbreak Due toJournal of fungi (Basel, Switzerland) · 2023Article
- Severe Sporotrichosis Caused by Sporothrix brasiliensis: Antifungal Susceptibility and Clinical OutcomesJournal of fungi (Basel, Switzerland) · 2022Article
- Sporotrichosis: A Review of a Neglected Disease in the Last 50 Years in Brazil.Microorganisms · 2022Review
- Sporotrichosis Caused by Non-Wild TypeFrontiers in cellular and infection microbiology · 2022Article
- Synthetic Derivatives against Wild-Type and Non-Wild-TypePharmaceuticals (Basel, Switzerland) · 2022Article
- In vitro activity of Schinus terebinthifolius extract and fractions against Sporothrix brasiliensis.Memorias do Instituto Oswaldo Cruz · 2022Article
- Clinical and epidemiological aspects of feline sporotrichosis caused by Sporothrix brasiliensis and in vitro antifungal susceptibility.Veterinary research communications · 2021Article
- Antifungal activity of Acylhydrazone derivatives againstAntimicrobial agents and chemotherapy · 2021Article
- Canine sporotrichosis: polyphasic taxonomy and antifungal susceptibility profiles of Sporothrix species in an endemic area in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Article
- Guideline for the management of feline sporotrichosis caused by Sporothrix brasiliensis and literature revision.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSporothrix brasiliensis is the most virulent sporotrichosis agent. This species usually responds to antifungal drugs, but therapeutic failure can occur in some patients. Antifungal susceptibility tests have been performed on this species, but no clinical breakpoints (CBPs) are available. In this situation, minimal inhibitory concentration (MIC) distributions and epidemiological cutoff values (ECVs) support the detection of identification of resistant strains.
objectivesTo study the MIC distributions of five antifungal drugs against S. brasiliensis and to propose tentative ECVs.
methodsMICs of amphotericin B (AMB), itraconazole (ITR), ketoconazole (KET), posaconazole (POS), and terbinafine (TRB) against 335 S. brasiliensis strains were determined by the Clinical and Laboratory Standards Institute broth microdilution method.
findingsThe proposed ECV, in µg/mL, for AMB, ITR, KET, POS, and TRB were 4.0, 2.0, 1.0, 2.0, and 0.25, respectively. Percentages of wild-type strains in our population for the above antifungal drugs were 98.48, 95.22, 95.33, 100, and 97.67%, respectively. MAIN
conclusionsThese ECVs will be useful to detect strains with resistance, to define CBPs, and to elaborate specific therapeutic guidelines for S. brasiliensis. Rational use of antifungals is strongly recommended to avoid the emergence of resistant strains and ensure the therapeutic effectiveness of sporotrichosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.